Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer’s Disease

Accumulating evidence suggests that the adiponectin (APN) paradox might be involved in promoting aging-associated chronic diseases such as Alzheimer’s disease (AD). In human brain, APN regulation of the evolvability of amyloidogenic proteins (APs), including amyloid-β (Aβ) and tau, in developmental/reproductive stages, might be paradoxically manifest as APN stimulation of AD through antagonistic pleiotropy in aging. The unique mechanisms underlying APN activity remain unclear, a better understanding of which might provide clues for AD therapy. In this paper, we discuss the possible relevance of activin, a member of transforming growth factor β (TGFβ) superfamily of peptides, to antagonistic pleiotropy effects of APN. Notably, activin, a multiple regulator of cell proliferation and differentiation, as well as an endocrine modulator in reproduction and an organizer in early development, might promote aging-associated disorders, such as inflammation and cancer. Indeed, serum activin, but not serum TGFβ increases during aging. Also, activin/TGFβ signal through type II and type I receptors, both of which are transmembrane serine/threonine kinases, and the serine/threonine phosphorylation of APs, including Aβ42 serine 8 and αS serine 129, may confer pathological significance in neurodegenerative diseases. Moreover, activin expression is induced by APN in monocytes and hepatocytes, suggesting that activin might be situated downstream of the APN paradox. Finally, a meta-analysis of genome-wide association studies demonstrated that two SNPs relevant to the activin/TGFβ receptor signaling pathways conferred risk for major aging-associated disease. Collectively, activin might be involved in the APN paradox of AD and could be a significant therapeutic target.

[1]  E. Masliah,et al.  Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease , 2021, Biomolecules.

[2]  H. Lashuel,et al.  Reverse engineering Lewy bodies: how far have we come and how far can we go? , 2021, Nature Reviews Neuroscience.

[3]  E. Masliah,et al.  Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease , 2020, Journal of Alzheimer's disease : JAD.

[4]  E. Masliah,et al.  Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability? , 2020, Frontiers in Endocrinology.

[5]  A. Xu,et al.  Higher Circulating Adiponectin Concentrations Predict Incident Cancer in Type 2 Diabetes - The Adiponectin Paradox. , 2020, The Journal of clinical endocrinology and metabolism.

[6]  G. Knott,et al.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration , 2020, Proceedings of the National Academy of Sciences.

[7]  Hiroshi I. Suzuki,et al.  TGF-β Signaling in Cellular Senescence and Aging-Related Pathology , 2019, International journal of molecular sciences.

[8]  E. Masliah,et al.  Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates , 2018, Journal of Parkinson's disease.

[9]  E. Masliah,et al.  Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases. , 2018, Drug discovery today.

[10]  Liang‐Kung Chen,et al.  The Association Between Serum Activin A Levels and Hypertension in the Elderly: A Cross-Sectional Analysis From I-Lan Longitudinal Aging Study , 2018, American journal of hypertension.

[11]  E. Masliah,et al.  Evolvability of Amyloidogenic Proteins in Human Brain , 2018, Journal of Alzheimer's disease : JAD.

[12]  G. Paolisso,et al.  Serum adiponectin levels are associated with worse cognitive function in postmenopausal women , 2017, PloS one.

[13]  C. Antoniades,et al.  Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease , 2017, British journal of pharmacology.

[14]  Frances Separovic,et al.  Phosphorylation of a full length amyloid-β peptide modulates its amyloid aggregation, cell binding and neurotoxic properties. , 2017, Molecular bioSystems.

[15]  A. van Maanen,et al.  Circulating Activin A predicts survival in cancer patients , 2017, Journal of cachexia, sarcopenia and muscle.

[16]  W. Greene,et al.  Semen amyloids participate in spermatozoa selection and clearance , 2017, eLife.

[17]  A. Murphy,et al.  Activin A more prominently regulates muscle mass in primates than does GDF8 , 2017, Nature Communications.

[18]  A. Yashin,et al.  Pleiotropic Associations of Allelic Variants in a 2q22 Region with Risks of Major Human Diseases and Mortality , 2016, PLoS genetics.

[19]  R. Wickner Yeast and Fungal Prions. , 2016, Cold Spring Harbor perspectives in biology.

[20]  C. Jack,et al.  Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. , 2016, Journal of Alzheimer's disease : JAD.

[21]  R. Derynck,et al.  TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. , 2016, Cold Spring Harbor perspectives in biology.

[22]  E. Masliah,et al.  Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[23]  D. D. de Kretser,et al.  Activins in reproductive biology and beyond. , 2016, Human reproduction update.

[24]  Ruitai Fan,et al.  Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation. , 2015, Oncology letters.

[25]  D. Franks,et al.  The evolution of prolonged life after reproduction. , 2015, Trends in ecology & evolution.

[26]  S. Brennecke,et al.  Genome-Wide Transcriptome Directed Pathway Analysis of Maternal Pre-Eclampsia Susceptibility Genes , 2015, PloS one.

[27]  Keith A. Johnson,et al.  The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials , 2014, Neuron.

[28]  G. Verleden,et al.  Role of activin-A in cigarette smoke-induced inflammation and COPD , 2013, European Respiratory Journal.

[29]  Sudha Seshadri,et al.  Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. , 2012, Archives of neurology.

[30]  C. Hellerbrand,et al.  Lipid accumulation impairs adiponectin-mediated induction of activin A by increasing TGFbeta in primary human hepatocytes. , 2011, Biochimica et biophysica acta.

[31]  M. Marsden,et al.  Integrin α5β1 Function Is Regulated by XGIPC/kermit2 Mediated Endocytosis during Xenopus laevis Gastrulation , 2010, PloS one.

[32]  C. Saunders,et al.  Comprehensive ZEB2 gene analysis for Mowat–Wilson syndrome in a North American cohort: A suggested approach to molecular diagnostics , 2009, American journal of medical genetics. Part A.

[33]  C. Hill,et al.  Tgf-beta superfamily signaling in embryonic development and homeostasis. , 2009, Developmental cell.

[34]  J. Schölmerich,et al.  Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. , 2009, Cytokine.

[35]  K. Tsuchida Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. , 2008, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[36]  M. Hedger,et al.  Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia , 2007, Proceedings of the National Academy of Sciences.

[37]  C. Donaldson,et al.  Pituitary actions of ligands of the TGF-β family: activins and inhibins , 2006 .

[38]  T. Kirkwood,et al.  Understanding the Odd Science of Aging , 2005, Cell.

[39]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[40]  F. Petraglia,et al.  Expression and secretion of activin A: possible physiological and clinical implications. , 2001, European journal of endocrinology.

[41]  A. Baccarelli,et al.  Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects , 2001, Experimental Gerontology.

[42]  K. Lewis,et al.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling , 2000, Nature.

[43]  S. Inoue,et al.  Follistatin is a developmentally regulated cytokine in neural differentiation. , 1992, The Journal of biological chemistry.

[44]  D. Robertson Transforming growth factor /inhibin family , 1991 .

[45]  W. Fischer,et al.  Activin is a nerve cell survival molecule , 1990, Nature.

[46]  H. Shibai,et al.  Mesodermal induction in early amphibian embryos by activin A (erythroid differentiation factor) , 1990, Roux's archives of developmental biology.

[47]  K. Titani,et al.  Activin-binding protein from rat ovary is follistatin. , 1990, Science.

[48]  N. Ling,et al.  Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. , 1987, Molecular endocrinology.

[49]  Joan Vaughan,et al.  Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid , 1986, Nature.

[50]  Naoto Ueno,et al.  Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin , 1986, Nature.

[51]  George C. Williams,et al.  PLEIOTROPY, NATURAL SELECTION, AND THE EVOLUTION OF SENESCENCE , 1957, Science of Aging Knowledge Environment.

[52]  K. Hruska,et al.  The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. , 2018, Kidney international.

[53]  P. Papageorgis Complex Interplay Between Aging and Cancer: Role of TGF-β Signaling. , 2017, Critical reviews in oncogenesis.

[54]  N. Laping Therapeutic uses of smad protein inhibitors: Selective inhibition of specific TGF-beta activities. , 1999, IDrugs : the investigational drugs journal.

[55]  K. Tsuchida,et al.  Activins and the receptor serine kinase superfamily. , 1995, Recent progress in hormone research.

[56]  N. Ueno,et al.  Activin as a cell differentiation factor. , 1990, Progress in growth factor research.

[57]  E. Daume,et al.  Purification of "inhibin" from human ovarian follicular fluid. , 1979, Acta endocrinologica.